Trials / Completed
CompletedNCT00965185
Statin Therapy to Improve Atherosclerosis in HIV Patients
Statin Therapy to Improve Inflammation and Atherosclerosis in HIV Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
In HIV patients, statin therapy will attenuate plaque inflammation, thus, making plaques less vulnerable, will deter plaque progression, and improve endothelial function. In addition to known cholesterol-lowering and C-reactive protein lowering effects, immunomodulatory effects of statins will lead to a shift from pro-inflammatory monocyte and T cell subsets to less atherogenic subpopulations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | atorvastatin | 20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months. |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2009-08-25
- Last updated
- 2017-12-11
- Results posted
- 2015-02-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00965185. Inclusion in this directory is not an endorsement.